Randall J. Bateman
YOU?
Author Swipe
View article: Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib
Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib Open
Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a pa…
View article: Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression Open
The cortical asymmetry index evaluates the cortical thickness asymmetry between hemispheres. We investigated cortical asymmetry index in asymptomatic and symptomatic mutation carriers of autosomal dominant Alzheimer’s disease to explore th…
View article: Early Detection and Monitoring of Amyloid‐Related Imaging Abnormalities in Monoclonal Antibody Therapy Using Generalized Diffusion Basis Spectrum Imaging (g‐DBSI): A Pilot Study
Early Detection and Monitoring of Amyloid‐Related Imaging Abnormalities in Monoclonal Antibody Therapy Using Generalized Diffusion Basis Spectrum Imaging (g‐DBSI): A Pilot Study Open
Background Amyloid‐Related Imaging Abnormalities (ARIA), characterized by vasogenic edema or sulcal effusions (ARIA‐E) or hemorrhagic lesions (microhemorrhages, superficial siderosis, or, rarely, microhemorrhages) (ARIA‐H), remain a signif…
View article: Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid Open
Brain amyloid-β (Aβ) pathology is a core feature of Alzheimer disease (AD) and can be quantified using positron emission tomography (PET). Cerebrospinal fluid (CSF) and plasma biomarkers detect abnormal Aβ, but it is unclear to what degree…
View article: Towards an AI biomedical scientist: Accelerating discoveries in neurodegenerative disease
Towards an AI biomedical scientist: Accelerating discoveries in neurodegenerative disease Open
Despite major advances in Alzheimer's disease and related diseases (ADRD) research, the translation of discoveries into impactful clinical interventions remains slow. Overwhelming data complexity, fragmented knowledge, and prolonged resear…
View article: Associations of lifestyle factors with amyloid pathology in persons without dementia
Associations of lifestyle factors with amyloid pathology in persons without dementia Open
Background The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective The aim of this study was to assess the association of alcohol consumption, smoking behavior, slee…
View article: Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers
Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers Open
Concentration-based fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer’s disease (AD) pathology. However, non-AD-related inter-individual variation in biofluids can also affect biomarker concen…
View article: Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies
Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies Open
Background: Early detection of cognitive decline in Alzheimer’s disease (AD), particularly in preclinical stages, is critical for evaluating therapeutic interventions. Traditional cognitive assessments often lack reliability and require le…
View article: Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease
Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease Open
INTRODUCTION Preclinical Alzheimer's disease (AD) can be described relative to biomarker positivity onset time. METHODS We estimated time from amyloid positivity (A+) using sampled iterative local approximation (SILA) in a longitudinal aut…
View article: Distribution of big tau isoforms in the human central and peripheral nervous system
Distribution of big tau isoforms in the human central and peripheral nervous system Open
Objective To characterize the distribution of “big tau,” a longer tau isoform expressed in the peripheral nervous system (PNS) and select central nervous system (CNS) regions, and to examine its relationship with aging and neurodegeneratio…
View article: Clinical progression on CDR‐SB©: Progression‐free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations
Clinical progression on CDR‐SB©: Progression‐free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations Open
INTRODUCTION Clinical Dementia Rating Sum of Boxes (CDR‐SB) is a reliable and clinically meaningful composite for assessing treatment effects in Alzheimer's disease (AD) clinical trials. Small CDR‐SB differences at the end of a trial often…
View article: The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology Open
BACKGROUND Tau‐derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid‐beta (Aβ) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long‐term anti‐Aβ antibodies on amyloid plaques, tau tangle…
View article: Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals Open
INTRODUCTION Plasma biomarkers’ utility for predicting incident mild cognitive impairment (MCI) remains unclear. We evaluated associations of plasma Alzheimer's disease (AD) biomarkers and amyloid positron emission tomography (PET) with tr…
View article: Addressing accuracy and hallucination of LLMs in Alzheimer's disease research through knowledge graphs
Addressing accuracy and hallucination of LLMs in Alzheimer's disease research through knowledge graphs Open
In the past two years, large language model (LLM)-based chatbots, such as ChatGPT, have revolutionized various domains by enabling diverse task completion and question-answering capabilities. However, their application in scientific resear…
View article: Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial Open
INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atro…
View article: Lecanemab Treatment in a Specialty Memory Clinic
Lecanemab Treatment in a Specialty Memory Clinic Open
Importance Two monoclonal antibodies targeting amyloid plaques, lecanemab and donanemab, have received traditional US Food and Drug Administration (FDA) approval for the treatment of early symptomatic Alzheimer disease (AD). The most signi…
View article: Ubiquitin–proteasome system in the different stages of dominantly inherited Alzheimer's disease
Ubiquitin–proteasome system in the different stages of dominantly inherited Alzheimer's disease Open
INTRODUCTION This study investigated the role of the ubiquitin–proteasome system (UPS) in dominantly inherited Alzheimer's disease (DIAD) by examining cerebrospinal fluid (CSF) levels of UPS proteins. METHOD The SOMAscan assay was used to …
View article: Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease Open
Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer's disease (AD). Clinical trials focused on cellular senescence are in early stages and have yet to establish reliable outcome measures …
View article: The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation
The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation Open
INTRODUCTION Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the diseas…
View article: Early increase of the synaptic blood marker β‐synuclein in asymptomatic autosomal dominant Alzheimer's disease
Early increase of the synaptic blood marker β‐synuclein in asymptomatic autosomal dominant Alzheimer's disease Open
INTRODUCTION β‐synuclein is a promising blood marker to track synaptic degeneration in Alzheimer's disease (AD) but changes in preclinical AD are unclear. METHODS We investigated serum β‐synuclein in 69 cognitively unimpaired mutation non‐…
View article: Impact of genetic counseling and testing in individuals at high risk of familial Alzheimer's disease from Latin America: a non‐randomized controlled trial
Impact of genetic counseling and testing in individuals at high risk of familial Alzheimer's disease from Latin America: a non‐randomized controlled trial Open
INTRODUCTION This study involved evaluating a tailored genetic counseling and testing (GCT) protocol for families at risk of autosomal dominant Alzheimer's disease (ADAD) in Latin America (LatAm), focusing on essential cultural and regiona…
View article: Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease Open
Insoluble tau aggregates within neurofibrillary tangles are a defining neuropathological feature of Alzheimer's disease (AD) and closely correlate with clinical symptoms. Although tau pathology can be assessed using tau positron emission t…
View article: Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials Open
Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer’s disease (AD), but their relative performance in predicting future cognitive decline among cognitively unimpaired (CU) individuals is…
View article: Harnessing Greater Statistical Power: Comprehensive Evaluation of Disease Modifying Treatment Effects Across All or Multiple Post-Baseline Visits Compared to the Last Visit for Alzheimer’s Disease Clinical Trials
Harnessing Greater Statistical Power: Comprehensive Evaluation of Disease Modifying Treatment Effects Across All or Multiple Post-Baseline Visits Compared to the Last Visit for Alzheimer’s Disease Clinical Trials Open
Background In Alzheimer’s disease (AD) clinical trials, efficacy inference is traditionally based on the last visit (e.g., 18 months). However, recent studies suggest that disease-modifying treatment effects may emerge as early as 3 months…
View article: Clinical Progression on CDR-SB<sup>©</sup>: Progression Free Time at Each 0.5-unit Level in Dominantly Inherited and Sporadic Alzheimer’s Disease Populations
Clinical Progression on CDR-SB<sup>©</sup>: Progression Free Time at Each 0.5-unit Level in Dominantly Inherited and Sporadic Alzheimer’s Disease Populations Open
INTRODUCTION CDR-SB is a reliable and clinically meaningful composite for assessing treatment effects in Alzheimer’s disease (AD) clinical trials. Small CDR-SB differences at the end of a trial often lead to controversy in deriving clinica…